Pinealon

EDR peptide

Grade D: Preclinical or anecdotal only

TL;DR: Pinealon (EDR tripeptide: Glu-Asp-Arg) is a synthetic peptide bioregulator developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. Its evidence base is thin and should be treated as preliminary. The sole citation in the reviewed literature is a theoretical review proposing possible epigenetic mechanisms by which EDR might interact with gene promoter regions relevant to Alzheimer's disease pathogenesis -- it is not a clinical study. Additional work from the same research group describes preclinical models (neuronal cell culture, transgenic mouse Alzheimer's models) showing reduced dendritic spine loss and modulation of neuroprotection-related gene expression. A small uncontrolled study in patients with traumatic brain injury consequences has been described in the literature, reporting improvements in memory and headache symptoms, but this was not a randomized or placebo-controlled design. No independent, controlled human trials have been conducted or published. Essentially all published research originates from a single Russian research lineage; none has been independently replicated by outside groups. The evidence cannot support any claim of clinical efficacy.

Key Takeaways

Grade D: Preclinical or anecdotal only
Not FDA approved: Pinealon has no FDA approval for any indication and is not on the FDA's approved drug list. It is classified as a research compound in the United States. The broader category of peptide bioregulators is under active regulatory review; individual compounds require their own PCAC evaluation before compounding pharmacies can lawfully prepare them.
Compounding: Its federal compounding status is not separately established in the FDA bulk-substance lists we verify; confirm current status with a licensed pharmacist or physician before any use.

Mechanism

The proposed mechanism is epigenetic regulation: EDR is hypothesized to enter cell nuclei and bind directly to promoter regions of genes involved in neuroprotection, antioxidant defense, and synaptic plasticity, modulating their transcription. This is based on molecular modeling and in vitro work. Whether this occurs in living humans at pharmacologically relevant concentrations has not been demonstrated.

Evidence

Pinealon (EDR tripeptide: Glu-Asp-Arg) is a synthetic peptide bioregulator developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. Its evidence base is thin and should be treated as preliminary. The sole citation in the reviewed literature is a theoretical review proposing possible epigenetic mechanisms by which EDR might interact with gene promoter regions relevant to Alzheimer's disease pathogenesis -- it is not a clinical study. Additional work from the same research group describes preclinical models (neuronal cell culture, transgenic mouse Alzheimer's models) showing reduced dendritic spine loss and modulation of neuroprotection-related gene expression. A small uncontrolled study in patients with traumatic brain injury consequences has been described in the literature, reporting improvements in memory and headache symptoms, but this was not a randomized or placebo-controlled design. No independent, controlled human trials have been conducted or published. Essentially all published research originates from a single Russian research lineage; none has been independently replicated by outside groups. The evidence cannot support any claim of clinical efficacy.

Safety and risks

No controlled human safety data exist. No consistent adverse signals appear in the reviewed literature, but the absence of rigorous trials means that absence of reported harm is not informative. Long-term safety in humans is completely unknown. As with all injectable research peptides, infection risk at injection site, immune reactions, and off-target effects are theoretical concerns that have not been systematically evaluated.

Compounding legality

Its federal compounding status is not separately established in the FDA bulk-substance lists we verify; confirm current status with a licensed pharmacist or physician before any use.

Sources

EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease. (2020) review

Pinealon is Not FDA approved. PeptideGrids presents evidence and regulatory status for informational purposes only. We do not sell, supply, source, or help anyone obtain this compound, and we provide no dosing or administration guidance. This is not medical advice; consult a licensed clinician. Full disclaimer.

Last reviewed June 2, 2026 by PeptideGrids editorial team (independently audited).